Table 3.
Selected characteristics and outcomes of Effective and Not-effective HAART users at the visit right before HAART initiation.
| Effectiveness | |||
|---|---|---|---|
| Characteristic | No | Yes | P |
| N=127 | N=127 | ||
| Age group | 0.43** | ||
| <35 y | 42 (33%) | 29 (23%) | |
| 35–39 y | 30 (24%) | 38 (30%) | |
| 40–44 y | 25 (20%) | 34 (27%) | |
| >=45 y | 30 (24%) | 26 (20%) | |
| Race | 0.31 | ||
| White | 16 (13%) | 25 (20%) | |
| Black | 81 (64%) | 75 (59%) | |
| Hispanic and Others | 30 (24%) | 27 (21%) | |
| CD4+ T-cell count (cells/mm3) | 0.17** | ||
| CD4>500 | 31 (24%) | 20 (16%) | |
| 200≤CD4 ≤500 | 62 (49%) | 69 (54%) | |
| CD4<200 | 34 (27%) | 38 (30%) | |
| Number of Male sex partners in the past 6 months | 0.97** | ||
| 0 | 34 (28%) | 38 (31%) | |
| 1 (married) | 20 (16%) | 17 (14%) | |
| 1 (single) | 54 (44%) | 47 (39%) | |
| >=2 | 15 (12%) | 20 (16%) | |
| Smoking status | 0.61** | ||
| None | 26 (22%) | 25 (22%) | |
| Former Smoker | 23 (19%) | 32 (29%) | |
| Current Smoker <10 pack years | 40 (34%) | 25 (22%) | |
| Current Smoker >=10 pack years | 29 (25%) | 30 (27%) | |
| Any HPV, number of individual HPV types | 0.99** | ||
| 0 | 50 (44%) | 40 (41%) | |
| 1 | 35 (30%) | 34 (35%) | |
| >1 | 30 (26%) | 23 (24%) | |
| Oncogenic HPV, number of individual HPV types | 0.34** | ||
| 0 | 82 (71%) | 73 (75%) | |
| 1 | 24 (21%) | 20 (21%) | |
| >1 | 9 (8%) | 4 (4%) | |
| Any SIL | 0.90** | ||
| No | 75 (79%) | 76 (79%) | |
| Low Grade SIL | 19 (20%) | 18 (19%) | |
| High Grade SIL | 1 (1%) | 2 (2%) | |
| Oncogenic HPV-positive SIL | 0.64 | ||
| No | 99 (93%) | 98 (91%) | |
| Yes | 8 (7%) | 10 (9%) | |
*
Limited to those contributing data to the present analysis. Some data were missing at baseline for selected patients. Percentages do not always add up to 100% due to rounding.
**
Two-sided Cochran-Mantel-Haenszel test. All other P values were determined with the two-sided Pearson’s chi-square test.